Riskpilot← Back to searchSign inGet full accessSvedala Pharma AB
ABActiveOrg 5593783375Regementsgatan 94Retail sale of pharmaceutical products · NACE 4773Est. 20223 employees
Revenue 2024
SEK 9,6M
+29% vs 2023
EBITDA margin
2.7%
+129% vs 2023
Equity ratio
11.2%
Financial strength
Net profit 2024
SEK 166K
+118% vs 2023
| Revenue | SEK 9,6M | +29% |
| EBITDA | SEK 257K | +129% |
| Net profit | SEK 166K | +118% |
| Total assets | SEK 2,2M | +10% |
| Equity | SEK 246K | +207% |
| Employees | 3 | — |
Legal name
Svedala Pharma AB
Org number
5593783375
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
2 maj 2022
Share capital
SEK 25 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Emam, Parviz Emam, Setareh Jennifer
Company purpose
Bolaget skall bedriva detaljhandel med läkemedel, dvs försäljning av läkemedel samt hygienvaror och hälsokostvaror till konsument samt därmed förenligt verksamhet.
Address
Regementsgatan 94
Email
jennifer@regementsapotek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 4 848 | 4 848 | 7 499 | 9 640 |
| Staff expenses | — | −1 038 | −1 682 | — |
| EBITDA | 47 | 47 | −887 | 257 |
| Depreciation & amort. | −5 | −5 | −28 | −35 |
| EBIT | 42 | 42 | −915 | 222 |
| Net financials | −3 | −0 | −10 | −36 |
| Profit before tax | 39 | 39 | −925 | 166 |
| Tax | −9 | 0 | — | −0 |
| Net profit | 30 | 30 | −925 | 166 |
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 2 440 | 2 440 | 2 003 | 2 204 |
| Equity | 55 | 55 | 80 | 246 |
| Long-term debt | 452 | 452 | 297 | 892 |
| Short-term debt | 1 933 | 1 933 | 1 625 | 1 066 |
| Total debt | 2 385 | 2 385 | 1 923 | 1 958 |
EBITDA margin
2.7%
This company
15.8%
Market median
-83% vs market
20222024
Equity ratio
11.2%
This company
38.2%
Market median
-71% vs market
20222024
Return on equity
67.5%
This company
18.4%
Market median
+267% vs market
20222024
Net profit margin
1.7%
This company
8.1%
Market median
-79% vs market
20222024
Asset turnover
4.37×
This company
1.12×
Market median
+290% vs market
20222024
Debt / equity
7.96×
This company
0.62×
Market median
-1184% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-02 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
EM Chief Auditor | Chief Auditor | 2022 | — | — |
MA | Audit | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Nebulosa Holding AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Nebulosa Holding AB
Svedala Pharma AB Board members of Svedala Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Setareh Jennifer Emam | Chief Executive Officer | 0 companies |
| Elvedin Music | Chief Auditor | 0 companies |
| Mats Anders Gyllenberg | Audit | 0 companies |
| Kobra Mona Fata | Deputy Board Member | 0 companies |
| Parviz Emam | Board of Directors | 0 companies |